Pedro Galhardo Bak-Gordon

Dr. Pedro Galhardo Bak-Gordon

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2019 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
JDJoana Desterro
Joana Desterro
PBPedro Galhardo Bak-Gordon
Pedro Galhardo Bak-Gordon
MCMaria Carmo-Fonseca
Maria Carmo-Fonseca

18 January 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
NCNoélia Custódio
Noélia Custódio
RSRosina Savisaar
Rosina Savisaar
CCCélia Carvalho
Célia Carvalho
PBPedro Galhardo Bak-Gordon
Pedro Galhardo Bak-Gordon
MRMaria I. Ribeiro
Maria I. Ribeiro
MCMaria Carmo-Fonseca
Maria Carmo-Fonseca
Predictive biomarkers are crucial in clarifying the best strategy to use poly(ADP-ribose) polymerase inhibitors (PARPi) for the greatest benefit to ovarian cancer patients. PARPi are specifically lethal to cancer cells that cannot repair DNA damage by homologous recombination (HR), and HR deficiency is frequently associated with BRCA1/2 mutations. Genetic tests for BRCA1/2 mutations are currently used in the clinic, but results can be inconclusive due to the high prevalence of rare DNA sequence variants of unknown significance. Most tests also fail to detect epigenetic modifications and mutations located deep within introns that may alter the mRNA. The aim of this study was to investigate whether quantitation of BRCA1/2 mRNAs in ovarian cancer can provide information beyond the DNA tests. Using the nCounter assay from NanoString Technologies, we analyzed RNA isolated from 38 ovarian cancer specimens and 11 normal fallopian tube samples. We found that BRCA1/2 expression was highly variable among tumors. We further observed that tumors with lower levels of BRCA1/2 mRNA showed downregulated expression of 12 additional HR genes. Analysis of 299 ovarian cancer samples from The Cancer Genome Atlas (TCGA) confirmed the coordinated expression of BRCA1/2 and HR genes. To facilitate the routine analysis of BRCA1/2 mRNA in the clinical setting, we developed a targeted droplet digital PCR approach that can be used with FFPE samples. In conclusion, this study underscores the potential clinical benefit of measuring mRNA levels in tumors when BRCA1/2 DNA tests are negative or inconclusive.

17 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
PXPeiqi Xing
Peiqi Xing
PBPedro Galhardo Bak-Gordon
Pedro Galhardo Bak-Gordon
JXJindou Xie
Jindou Xie
JZJian Zhang
Jian Zhang
ZLZhaoqi Liu
Zhaoqi Liu
JMJames L. Manley
James L. Manley
SF3B1 is the most frequently mutated splicing factor in cancer. Mechanistically, such mutations cause missplicing by promoting aberrant 3’ splice site usage; however, how this occurs remains controversial. To address this issue, we employed a computational screen of 600 splicing-related proteins to identify those whose reduced expression recapitulated mutant SF3B1 splicing dysregulation. Strikingly, our analysis revealed only two proteins whose loss reproduced this effect. Extending our previous findings, loss of the G-patch protein SUGP1 recapitulated almost all splicing defects induced by SF3B1 hotspot mutations. Unexpectedly, loss of the RNA helicase Aquarius (AQR) reproduced ∼40% of these defects. However, we found that AQR knockdown caused significant SUGP1 missplicing and reduced protein levels, suggesting that AQR loss reproduced mutant SF3B1 splicing defects only indirectly. This study advances our understanding of missplicing caused by oncogenic SF3B1 mutations, and highlights the fundamental role of SUGP1 in this process.